LSL Pharma Group Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	May '26 May 20, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jul '22 Jul 31, 2022
Market Cap	42	41	43	40	-	-
Market Cap Growth	8.01%	-4.75%	8.10%	-	-	-
Enterprise Value	64.03	77.41	62.89	50.91	0	0
Last Close Price	0.35	0.35	0.41	0.49	-	-
PE Ratio	15.43	-	13.67	-	-	-
PS Ratio	1.58	1.43	2.44	3.99	-	-
PB Ratio	1.67	1.53	1.74	4.62	-	-
P/TBV Ratio	1.53	1.53	1.74	4.51	-	-
EV/Sales Ratio	2.39	2.69	3.54	5.08	-	-
EV/EBITDA Ratio	15.96	193.04	26.96	-	-	-
EV/EBIT Ratio	45.25	-	76.32	-	-	-
Debt / Equity Ratio	1.36	1.36	0.80	1.26	2.68	-
Debt / EBITDA Ratio	95.64	95.64	9.37	-	-	-
Net Debt / Equity Ratio	1.40	1.40	0.87	1.88	3.00	-
Net Debt / EBITDA Ratio	94.27	94.27	9.24	-18.69	-1.23	-
Net Debt / FCF Ratio	-8.47	-8.47	-4.52	-2.10	-3.82	-
Asset Turnover	0.45	0.45	0.42	0.34	0.60	0
Inventory Turnover	2.19	2.19	1.86	2.37	7.02	-
Quick Ratio	0.59	0.59	0.54	0.18	0.11	-
Current Ratio	2.34	2.34	1.59	0.48	0.38	-
Return on Equity (ROE)	-10.87%	-10.87%	19.78%	-121.50%	-315.83%	0.00%
Return on Assets (ROA)	-3.24%	-3.24%	1.92%	-6.87%	-102.01%	0.00%
Return on Invested Capital (ROIC)	-3.59%	-3.59%	2.23%	-8.67%	-132.06%	0.00%
Return on Capital Employed (ROCE)	-3.93%	-3.93%	2.76%	-12.68%	-179.76%	0.00%
Earnings Yield	6.54%	-	7.32%	-	-	-
Buyback Yield / Dilution	-19.11%	-11.58%	-31.13%	-19.66%	-	-
Total Shareholder Return	-19.11%	-11.58%	-31.13%	-19.66%	-	-

Updated Apr 29, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.